A clinical trial showed that SCS provided pain relief in patients with PDPN…. 

In patients with type 2 diabetes, LX4211 produced greater dose-ranging effects on HbA1c than on glucosuria…. 

High-intensity statin therapy altered the progressive nature of coronary atheroma in diabetic and nondiabetic patients….

A long-term British study revealed that there are correlations between childhood TV viewing time and adult TV viewing time…. 

Weight loss outcomes are comparable among named diet programs…. 

Vagal nerve blockade might not be an effective therapy for obesity treatment…. 

Better dietary quality links to higher socioeconomic status…. 

When Al Mann first said he was going to develop an inhaled insulin, many thought he was beating a dead horse after the collective experiences with Exubera. They forgot that Al had already built the most successful pump company of all times, and that he did not like to fail. …

Diabetes is a huge and growing problem, and the costs to society are high and escalating. More was spent in 2013 in North America and the Caribbean than in any other region. The Top 5 countries for prevalence in North America and the Caribbean are: Belize, Guyana, Curacao, Martinique, and …

  With this week’s Homerun Slides, we have a short special presentation for you on the new inhaled insulin, Afrezza, that goes with our exclusive interview by our publisher, Steve Freed, with the founder and CEO of Mannkind Corp, Al Mann….